Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2015 | 09-2015 | 06-2015 | 03-2015 | 12-2014 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -32,231 | -36,549 | -12,089 | -15,108 | -68,375 |
| Depreciation Amortization | 1,677 | 1,917 | 1,364 | 746 | 3,219 |
| Accounts receivable | -23,261 | 757 | -589 | 1,424 | -52 |
| Other Working Capital | -29,497 | -3,727 | -4,739 | -3,779 | 106 |
| Other Operating Activity | 46,229 | 15,716 | 11,152 | 2,878 | 17,584 |
| Operating Cash Flow | $-37,083 | $-21,886 | $-4,901 | $-13,839 | $-47,518 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 8,248 | 21,370 | 741 | -10,290 | -31,583 |
| PPE Investments | -2,360 | -726 | -390 | -130 | -1,368 |
| Investing Cash Flow | $5,888 | $20,644 | $351 | $-10,420 | $-32,951 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 13,098 | 11,367 | 10,930 | 7,157 | 114,501 |
| Financing Cash Flow | $13,098 | $11,367 | $10,930 | $7,157 | $114,501 |
| Beginning Cash Position | 61,889 | 61,389 | 61,389 | 61,389 | 27,357 |
| End Cash Position | 43,792 | 71,514 | 67,769 | 44,287 | 61,389 |
| Net Cash Flow | $-18,097 | $10,125 | $6,380 | $-17,102 | $34,032 |
| Free Cash Flow | |||||
| Operating Cash Flow | -37,083 | -21,886 | -4,901 | -13,839 | -47,518 |
| Capital Expenditure | -2,360 | -726 | -390 | -130 | -1,368 |
| Free Cash Flow | -39,443 | -22,612 | -5,291 | -13,969 | -48,886 |